Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery

Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery

Introduction: Although third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected stage IIIA non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, the optimal treatment sequencing of EGFR-TKIs, p...

Full description

Bibliographic Details
Main Authors: Wenyan Ma, Ziyi Sheng, Yongliang Niu, Bo Yan, Yong Chen, Haitang Yang, Rong Li
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:Heliyon
Subjects:
EGFR mutation
Lung adenocarcinoma
Stage IIIA
Osimertinib
First-generation TKIs
Treatment sequential
Online Access:http://www.sciencedirect.com/science/article/pii/S240584402308163X

Similar Items

Similar Items